Trial Profile
Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 07 Dec 2010 New trial record